This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Hypertension, Vol 7, 1008-1016, Copyright © 1985 by American Heart Association

ARTICLES

Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Veterans Administration Cooperative Study Group on Antihypertensive Agents

To evaluate the short-term and long-term effectiveness of propranolol and hydrochlorothiazide monotherapy for hypertension, 683 hypertensive men were randomized to treatment with either propranolol or hydrochlorothiazide. Both drugs increased the average fasting plasma glucose level by approximately 5 mg/dl after 10 weeks (p less than 0.001) and 1 year (p less than 0.001) of treatment, but the elevation persisted only in the propranolol-treated group 1 month after discontinuing the year-long treatment (p less than 0.01). A subset of 191 patients had 2-hour glucose tolerance tests. Hydrochlorothiazide increased the average 2-hour oral glucose tolerance test result by 18.0 mg/dl after 10 weeks (p less than 0.001), an increase significantly higher than that induced by propranolol (p less than 0.012). After 1 year of treatment, however, propranolol also increased the average 2- hour oral glucose tolerance test result (p less than 0.05) and there was no significant difference between drugs. The hyperglycemic effects were dose-related, which suggests that both drugs should be administered at their lowest effective dosage. The clinical importance of the persistent fasting plasma glucose elevation in propranolol- treated patients 1 month after discontinuing treatment is unknown.

This article has been cited by other articles:

				D. K McGuire, J. R Winterfield, J. A Rytlewski, and E. Ferrannini Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus Diabetes and Vascular Disease Research, March 1, 2008; 5(1): 59 - 66. [Abstract] [PDF]

				C. J. Pepine and R. M. Cooper-DeHoff Cardiovascular therapies and risk for development of diabetes J. Am. Coll. Cardiol., August 4, 2004; 44(3): 509 - 512. [Abstract] [Full Text] [PDF]

				R. Dusing and H. Lehnert Diabetogenic effect of antihypertensive treatment: primum nil nocere Nephrol. Dial. Transplant., March 1, 2004; 19(3): 531 - 534. [Full Text] [PDF]

				B. Luna and M. N. Feinglos Drug-Induced Hyperglycemia JAMA, October 24, 2001; 286(16): 1945 - 1948. [Full Text] [PDF]

				T. W. Gress, F. J. Nieto, E. Shahar, M. R. Wofford, F. L. Brancati, and The Atherosclerosis Risk in Communities Study Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus N. Engl. J. Med., March 30, 2000; 342(13): 905 - 912. [Abstract] [Full Text] [PDF]

				W. H. Frishman, B. S. Bryzinski, L. R. Coulson, V. L. DeQuattro, N. D. Vlachakis, W. J. Mroczek, G. Dukart, J. D. Goldberg, D. Alemayehu, and K. Koury A Multifactorial Trial Design to Assess Combination Therapy in Hypertension: Treatment With Bisoprolol and Hydrochlorothiazide Arch Intern Med, July 11, 1994; 154(13): 1461 - 1468. [Abstract] [PDF]